/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

C

Cem Demirkiran

Yale New Haven Hospital(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

64

Papers

211

Citations

8

h-index

6

i10-index

Cem Demirkiran is an academic researcher from Yale New Haven Hospital. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Ovarian cancer diagnosis and treatment & Estrogen and related hormone effects. The author has an h-index of 8, co-authored 55 publications.

ORCID: 0000-0002-7073-2819

Research Topics

HER2/EGFR in Cancer Research Ovarian cancer diagnosis and treatment Estrogen and related hormone effects Cytokine Signaling Pathways and Interactions Monoclonal and Polyclonal Antibodies Research

Papers by this author

works

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression

2023 · Gynecologic Oncology · 23 citations

https://doi.org/10.1016/j.ygyno.2022.12.018

Dennis Mauricio Stefania Bellone Levent Mutlu Blair McNamara

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy

2023 · Gynecologic Oncology Reports · 9 citations

https://doi.org/10.1016/j.gore.2023.101218

Blair McNamara Stefania Bellone Cem Demirkiran Tobias M.P. Hartwich

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2

2024 · Clinical & Experimental Metastasis · 9 citations

https://doi.org/10.1007/s10585-024-10297-z

Levent Mutlu Blair Mcnamara Stefania Bellone Diego Manavella

<i>In Vivo</i> and <i>In Vitro</i> Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma

2023 · Molecular Cancer Therapeutics · 8 citations

https://doi.org/10.1158/1535-7163.mct-23-0126

Levent Mutlu Diego Manavella Stefania Bellone Blair McNamara

Role of systematic lymphadenectomy at the time of cytoreductive surgery among non-high grade serous epithelial ovarian cancers

2025 · Gynecologic Oncology · 0 citations

https://doi.org/10.1016/j.ygyno.2025.04.320

Michelle Greenman Cem Demirkiran Blair McNamara Gary Altwerger

Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis

2025 · Gynecologic Oncology · 0 citations

https://doi.org/10.1016/j.ygyno.2025.09.017

Victoria M. Ettorre Stefania Bellone Natália Buza Pei Hui

Research topics

topics

HER2/EGFR in Cancer Research

Ovarian cancer diagnosis and treatment

Estrogen and related hormone effects

Cytokine Signaling Pathways and Interactions

Monoclonal and Polyclonal Antibodies Research

Chat about Author

Papers

Chat

Click to start Chat